Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5945
    -0.0004 (-0.07%)
     
  • NZD/EUR

    0.5554
    +0.0014 (+0.25%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.70
    +0.13 (+0.16%)
     
  • GOLD

    2,348.80
    +6.30 (+0.27%)
     
  • NASDAQ

    17,752.33
    +321.83 (+1.85%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,286.53
    +200.73 (+0.53%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.7560
    +1.2600 (+1.36%)
     

MS, USB, ABT & TXT Leads Q1 Earnings

SNE vs. DLB: Which Stock Is the Better Value Option?

Triple-digit gains in regular-day Tuesday trading in both the Dow and Nasdaq were bolstered by a number of different things — strong housing starts and a lack of relative geopolitical tension early this week among them — but nothing so influential as a very strong Q1 earnings season. We are still in the early stages so far (only a week has passed since Delta Air Lines beat estimates on both top and bottom lines), but overall results have been notably better than expected.

While after-the-bell earnings reports yesterday were better than expected across the board, some companies performed more impressively than others. While Intuitive Surgical ISRG posted a robust earnings beat, IBM IBM eked out a positive surprise on new corporate tax benefits alone. (IBM’s Watson enterprise has thus far failed to inspire fresh investment in Big Blue.) As a result, IBM has shed more than 5% in today’s pre-market, while ISRG shares are up 5% this morning.

New Q1 earnings reports are following suit, starting with Morgan Stanley MS, which left estimates in the dust this morning. This investment banking major posted $1.45 per share on $11.1 billion in quarterly revenues, outpacing the $1.28 and $10.5 billion in the Zacks consensus estimates, respectively. Net income grew 38% in Q1, whereas Sales & Trading rose 26%. For more on MS’s earnings, click here.

Fellow financial institution U.S. Bank USB beat earnings estimates by a penny to 95 cents per share, but missed on revenue expectations, bringing in $5.47 billion as opposed to the $5.53 billion our analysts were looking for. This still represents good year-over-year growth from $5.29 billion in Q1 2017, but pre-market trading shows USB shares slipping half a percentage point at this hour. For more on USB’s earnings, click here.

ADVERTISEMENT

Based on Chicago’s North Shore, Abbott Labs ABT also topped earnings consensus by a penny to 59 cents per share. Revenues also slightly surpassed expectations in Q1, reporting $7.39 billion in sales. Guidance for full-year 2018 has been posted at between $2.80 and $2.90 per share, and the Zacks consensus is roughly at the midpoint. Shares are off 1.3% ahead of today’s opening bell. For more on ABT’s earnings, click here.

Defense components major Textron TXT, however, performed much better this morning — 76 cents per share blew away expectations of 46 cents, and more than double the 37 cents per share a year ago. Sales of $3,296 million also impressed, both above the estimated $3,114 million and the year-ago figure of $3,093 million. Industrial sales perked up 14%, and the company saw gains from its Arctic Cat acquisition. Shares are up 6.7% in today’s pre-market. For more on TXT’s earnings, click here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
International Business Machines Corporation (IBM) : Free Stock Analysis Report
 
U.S. Bancorp (USB) : Free Stock Analysis Report
 
Abbott Laboratories (ABT) : Free Stock Analysis Report
 
Textron Inc. (TXT) : Free Stock Analysis Report
 
Morgan Stanley (MS) : Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research